FDA issues warning letter over mailer

Share this article:
The FDA has issued Eli Lilly a warning letter over effectiveness claims the company made in a 2005 promotional mailer to physicians for its blockbuster antidepressant/nerve pain treatment Cymbalta.

In a letter posted to the FDA's Web site, the agency said Lilly's promotion intended to promote its indication as a treatment for diabetic nerve pain was “false and misleading” and omitted some of the most serious and important risk information associated with its use.

The agency asked that Lilly stop using the material or any similar promos. A spokesman told The Indianapolis Star that the company is working with the FDA “to gain a greater understanding of their concerns.” The spokesman said Lilly will take action once it has “more clarity” on the agency's comments.

Launched in 2004, Cymbalta has become Lilly's fastest-growing drug, with global sales of $1.3 billion in 2006.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?